Achievements

Major Achievements:

Antibiotics therapy for early HP-positive large cell lymphoma of the stomach

Results of TCOG MALToma studies provided strong supportive evidences for using anti HP antibiotics therapy as first line treatment for both low grade and high grade early stage MALToma patients.

Chemotherapy-induced reactivation of HBV monitoring and pre-emptive treatment

Results of TCOG serial Lymphoma studies provided solid evidence for the National Health Insurance Administration to agree the reimbursement of antiviral prophylaxis in cancer patients of HBV carrier undergoing chemotherapy.

Developing novel chemotherapy regimens for advanced pancreatic-biliary cancers

Based on the promising result of pancreatic studies, GOFL48 regimen has become the most popular chemotherapy regimen for advanced pancreatic cancer in Taiwan. TCOG continues to conduct trials to improve treatment outcome in this most devastating malignancy.

Randomized trial for adjuvant antiviral therapy after HCC surgery

The prospective study has shown that the long-term outcomes of viral hepatitis-related HCC with curative resection were not affected by adjuvant IFNα-2b therapy in this chronic HBV infection endemic area, but this is the first multicenter study to achieve such excellent outcomes in HCC after surgical resection. The finding that HbeAg seropositivity can serve as an independent adverse prognostic factors for RFS highlights the potential for more potent HBV suppression therapy in preventing and/or reducing recurrence in postoperative HBV-related HCC patients. More potent antiviral therapy deserves to be explored for this patient population.

Publications

  1. T1309 — “Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximabbased concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: final analysis of a phase 2 clinical trial”. Yen CJ, Tsou HH, Hsieh CY, Chu CY, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY, Chang KY. Head & Neck. June 2019; 41:1703-1712.
  2. T1303 –“Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study”. Hong RL, Hsiao CF, Ting LL, Ko JY, Wang CW, Chang JTC, Lou PJ, Wang HM, Tsai MH, Lai SC, Liu TW. Ann Oncol. 2018 Sep 1;29(9):1972-1979.
  3. T1408 — “Quantification of HBV Core Antibodies May Help Predict HBV Reactivation in Patients with Lymphoma and Resolved HBV Infection”. Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. J Hepatol. 2018 Aug; 69(2):286-292.
  4. T3211 — “The Clinical Impact of the Novel Tumor Marker DR-70 in Unresectable Gastric Cancer Patients”. Hung YP, Chen MH, Lin JS, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. J Chin Med Assoc. 2018 Jul; 81(7):593-598.
  5. T1210-”Expression Levels of ROS1/ALK/c-MET and Therapeutic Efficacy of Cetuximab plus Chemotherapy in Advanced Biliary Tract Cancer”. Chiang NJ, Hsu C, Chen JS, Tsou HH, Shen YY, Chao Yee, Chen MH, Yeh TS, Shan YS, Huang SF, Chen LT.  Sci Rep. 2016 May 3; 6:25369.
  6. T3211- “Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial”. Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC, Chen LT, Liu TW, Li CP, Chao Y. AMedicine (Baltimore). 2016 Jan; 95(3):e2565.
  7. T1394-“Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncology”. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan TC, Huang PY, Benhamou E, Zhu G, Chua TT, Chen Y, Mai HQ, Kwong LW, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui P, Lu TX, Bourhis J, Pignon P, on behalf of the MAC-NPC Collaborative Group. 2015 Jun; 16:645-55.
  8. T1210-“A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer”. Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT, on behalf of the TCOG. Annals Oncology. 2015 May; 26(5):943-9.
  9. T1405-“Long-term Results of A Phase II Trial with Frontline Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Localized Nasal Natural Killer/T-cell Lymphoma”. Tsai HJ, Lin SF, Chen CC, Chen TY, Su WC, Hwang WL, Lin JC, Chiou TJ, Kao WY, Chiu CF, Chang YF, Chang SM, Chang MC, Su IJ. Eur J Haematol. 2015 Feb; 94(2):130-7.
  10. T1408-“Chemotherapy-Induced Hepatitis B Reactivation in Lymphoma Patients with Resolved HBV Infection: A Prospective Study”. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL; Taiwan Cooperative Oncology Group. Hepatology. 2014 Jun; 59(6):2092-100.
  11. T2207-“Celecoxib plus Chemoradiotherapy for Locally Advanced Rectal Cancer: A Phase II TCOG Study”. Wang LW, Hsiao CF, Chen WT, Lee HH, Lin TC, Chen HC, Chen HH, Chien CR, Lin TY, Liu TW. J Surg Oncol. 2014 May; 109(6):580-5.
  12. T1297-“Long-term Results of a Randomized, Observation-controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma after Curative Resection”. Chen LT, Chen MF, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ; Disease Committee of Adjuvant Therapy for Postoperative Hepatocellular Carcinoma, TCOG, NHRI. Ann Surg. 2012 Jan; 255(1):8-17.
  13. T1309-“A Phase II Study of Neoadjuvant Bio-chemotherapy with Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Head and Neck Cancer – Representative of Head and Neck Cancer Study Group of Taiwan Cooperative Oncology Group”. Chang KY, Yen CJ, Hsieh CY, Tsou HH, Chiu CF, Chen CC, Tsao CJ, Tsai KY, Tsai ST, Chang JY. E ur J Cancer. 2011; 47:S547-S548.
  14. T1204-“Induction chemotherapy with gemcitabine, oxaliplatin, and 5-Fluorouracil/ Leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study”. Ch’ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):e749-57.
  15. T1401-“A Revisit for Prophylactic Lamivudine for Chemotherapy-associated Hepatitis B Reactivation in Non-Hodgkin’s Lymphoma: a Randomized Trial”. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, Hsiao HH, Young JH, Chang MC, Liao YM, Li CC, Wu HB, Tien HF, Chao TY, Liu TW, Cheng AL and Chen PJ. Hepatology, 2008 Mar; 47(3):844-53.
  16. T1899 LAB-“Human Papillomaviral Load Changes in Low-grade Squamous Intraepithelial Lesions of the Uterine Cervix”. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, Hsieh CY. Br J Cancer. 2006 Nov 20; 95(10):1384-9.
  17. T1899-“The Distribution and Differential Risks of Human Papillomavirus Genotypes in Cervical Preinvasive Lesions: A Taiwan Cooperative Oncologic Group (TCOG) Study”. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, Kan YY, Chuang MH, Chu TY, Hsieh CY; Taiwan Cooperative Oncologic Group. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1801-8.
  18. T1899-“Epidemiologic Correlates of Cervical Human Papillomavirus Prevalence in Women with Abnormal Pap Smear Tests: A Taiwan Cooperative Oncology Group (TCOG) Study”. Sun CA, Hsiung CA, Lai CH, Chen CA, Chou CY, Ho CM, Twu NF, Feng WL, Chuang MH, Hsieh CY, Chu TY. J Med Virol. 2005 Oct; 77(2):273-81.
  19. T1296-“Long-Term Results of Anti-helicobacter pylori Therapy in Early-stage Gastric High-grade Transformed MALT Lymphoma”. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL. J Natl Cancer Inst. 2005 Sep 21; 97(18):1345-53.
  20. T1296-“Nuclear Expression of BCL10 or Nuclear Factor Kappa B Helps Predict Helicobacter Pylori-independent Status of Low-grade Gastric Mucosa-associated Lymphoid Tissue Lymphomas with or without t(11;18)(q21;q21)”. Yeh KH, Kuo SH, Chen LT, Mao TL, Doong SL, Wu MS, Hsu HC, Tzeng YS, Chen CL, Lin JT, Cheng AL. Blood. 2005 Aug 1; 106(3):1037-41.
  21. T1495-“Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients”. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J Gastroenterol. 2005 Sep 14; 11(34):5283-8.
  22. T1495-“Steroid-Free Chemotherapy Decreases Risk of Hepatitis B Virus (HBV) Reacti­vation in HBV-carriers with Lymphoma”. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J; Lymphoma Committee of TCOG. Hepatology. 2003 Jun; 37(6): 1320-8.
  23. T1394-“A Phase III Study of Adjuvant Chemotherapy in Advanced Nasopharyngeal Carcinoma Patients”. Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, Wang LW, Lai YL, Hsu MM, Lian SL, Chang CH, Liu TW, Chin YH, Yen SH, Perng CH, Chen KY. Int J Radiat Oncol Biol Phys. 2002 Apr 1; 52(5):1238-44.
  24. T1188-“Weekly CAF Chemotherapy for Advanced Breast Cancer Patients”. Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ, Chen LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Oncology. 1997 Jul-Aug; 54(4):293-7.

[BIG International Trials]

  1. APHINITY- “Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer”. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators (Liu TW). N Engl J Med. 2017 Jul 13; 377(2):122-131.
  2. NeoALTTO-“Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial”. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lancet. 2012 Feb 18; 379(9816):633-40.
  3. HERA - “Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial”. Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu TW, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. J Clin Oncol. 2010 July; 28(21):3422-8.
  4. HERA-“Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer”. Piccart-Gebhart MJ1, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team. N Engl J Med. 2005 Oct 20; 353(16):1659-72.
Share Button

Comments are closed.